Cardiac Syndrome X with Microvascular Spasm on Acetylcholine Testing — What to Do When Calcium Channel Blocker Therapy Fails to Control Anginal Symptoms
In patients with Cardiac syndrome X, acetylcholine (Ach) provocation testing can reveal microvascular spasm. When anginal symptoms persist alongside ischaemic ECG changes and angiographic coronary lumen reduction below 90%, the diagnostic picture points to ongoing microvascular involvement despite initial treatment.
Clinical Scenario
Microvascular spasm confirmed on acetylcholine testing, with anginal symptoms and ischaemic ECG changes. Angiographic lumen reduction is less than 90%, consistent with microvascular rather than macrovascular (epicardial) spasm.
First-Line Treatment — Insufficient Response
A calcium channel blocker (CCB) was initiated as first-line therapy for microvascular vasospasm. The primary goal — control of anginal symptoms — was not achieved, indicating the need to escalate to the next treatment step.
Next Step
When initial CCB therapy has not controlled symptoms, the evidence-based protocol specifies a further step within the calcium channel blocker class. The complete regimen, including the specific approach and any additional management considerations, is available in the full protocol.
References
DOI: 10.1093/eurheartj/ehae177
If the lumen reduction is <90%, the diagnosis of microvascular spasm is made.
The test is considered positive for macrovascular spasm if symptoms occur, accompanied by ischaemic ECG changes and an angiographic ≥90% reduction of the coronary lumen.
In patients with either epicardial or microvascular spasm following Ach testing, calcium antagonists should be considered as first-line therapy.
View source ↗